Valeant Pharmaceuticals Intl Inc (VRX): an Asset Undermined

Valeant Pharmaceuticals Intl Inc (VRX): an Asset Undermined

Asset sales have added to the bearish sentiment lately, but there is something that investors are ignoring

Healthcare

Valeant Pharmaceuticals International, Inc. (NYSE:VRX): What About Bausch & Lomb?

The near-term results of Bausch & Lomb are not so bright, as market experts are aligning its performance to the shrinking portfolio of the company

Valeant Pharmaceuticals International, Inc. (NYSE:VRX): Here's Why The Game is not Over yet

Recent Facts Suggest that investors have underestimated the Laval-based company's potential

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Continues to Lighten Debts

Analysts would eye the upcoming earnings due later this month, while the company is expected to give a lower guidance amid recent developments

Merck & Co., Inc. (NYSE:MRK): Upgraded To Overweight

FDA Lung Cancer Boost For Keytruda Drives Upgrade for Merck by PiperJaffray

Gilead Sciences, Inc. (NASDAQ:GILD) Adds Flexibility to M&A Philosophy

BMO Capital Markets key takeaways after meeting with management